Suppr超能文献

氟卡尼与胺碘酮:婴儿难治性快速性心律失常的联合治疗

Flecainide and amiodarone: combined therapy for refractory tachyarrhythmias in infancy.

作者信息

Fenrich A L, Perry J C, Friedman R A

机构信息

Section of Pediatric Cardiology, Texas Children's Hospital, Houston 77030.

出版信息

J Am Coll Cardiol. 1995 Apr;25(5):1195-8. doi: 10.1016/0735-1097(94)00513-p.

Abstract

OBJECTIVES

This study assessed the safety and efficacy of combined flecainide and amiodarone therapy in controlling refractory tachyarrhythmias in infants.

BACKGROUND

Single-drug as well as standard combination medical therapy for tachyarrhythmias in infants sometimes fails. In those cases, one may consider interventional therapy. However, this option may carry a high risk of morbidity and mortality in infants. The natural history of tachyarrhythmias in infants often favors eventual resolution and reinforces the importance of selecting an effective medical regimen.

METHODS

We performed a retrospective analysis of nine infants (median age 2 months) who received combined flecainide and amiodarone therapy for attempted control of refractory tachyarrhythmias. Trough serum drug levels of flecainide were monitored, and 24-h ambulatory electrocardiographic monitoring was used to determine efficacy of therapy.

RESULTS

Single-drug treatment with flecainide or amiodarone failed in all of the infants studied. An average of four drugs failed (range one to six) before administration of combined flecainide and amiodarone therapy. During combined therapy, the flecainide dose was 70 to 110 mg/m2 per day, and that for amiodarone was 7.5 to 13.5 mg/kg per day for a mean (+/- SD) of 9 +/- 2 days to load and 5 to 12 mg/kg per day as maintenance. Successful control of tachyarrhythmias was demonstrated in seven (78%) of nine infants (95% confidence interval 46% to 99%) (three of three with congenital junctional ectopic tachycardia, three of three with supraventricular tachycardia and one of three with ventricular tachycardia). During combined therapy, flecainide trough levels ranged from 350 to 731 ng/ml. Corrected QT intervals varied from 0.440 to 0.488 ms. No proarrhythmia occurred. None of the infants required a pacemaker, and all had normal left ventricular dimensions and fractional shortening by echocardiography. Eight of nine infants had a structurally normal heart. One infant had surgical correction of an atrioventricular septal defect.

CONCLUSIONS

Combination therapy with flecainide and amiodarone appears to be safe and effective in controlling refractory tachyarrhythmias in infants. The combination of flecainide and amiodarone may obviate the need for early interventional therapy or may allow delay until the child is older.

摘要

目的

本研究评估了氟卡尼与胺碘酮联合治疗对控制婴儿难治性快速心律失常的安全性和有效性。

背景

婴儿快速心律失常的单药治疗以及标准联合药物治疗有时会失败。在这些情况下,可能会考虑介入治疗。然而,这种选择在婴儿中可能具有较高的发病和死亡风险。婴儿快速心律失常的自然病程通常有利于最终缓解,并强化了选择有效药物治疗方案的重要性。

方法

我们对9名婴儿(中位年龄2个月)进行了回顾性分析,这些婴儿接受氟卡尼与胺碘酮联合治疗以尝试控制难治性快速心律失常。监测氟卡尼的谷血清药物水平,并使用24小时动态心电图监测来确定治疗效果。

结果

在所研究的所有婴儿中,氟卡尼或胺碘酮的单药治疗均失败。在给予氟卡尼与胺碘酮联合治疗之前,平均有四种药物治疗失败(范围为1至6种)。联合治疗期间,氟卡尼剂量为每天70至110mg/m²,胺碘酮剂量为每天7.5至13.5mg/kg,平均(±标准差)负荷期为9±2天,维持期为每天5至12mg/kg。9名婴儿中有7名(78%)(95%置信区间46%至99%)的快速心律失常得到成功控制(3例先天性交界性异位性心动过速患儿中的3例、3例室上性心动过速患儿中的3例以及3例室性心动过速患儿中的1例)。联合治疗期间,氟卡尼谷水平范围为350至731ng/ml。校正QT间期在0.440至0.488ms之间变化。未发生促心律失常。没有婴儿需要起搏器,并且通过超声心动图检查所有婴儿的左心室尺寸和缩短分数均正常。9名婴儿中有8名心脏结构正常。1名婴儿接受了房室间隔缺损的手术矫正。

结论

氟卡尼与胺碘酮联合治疗在控制婴儿难治性快速心律失常方面似乎是安全有效的。氟卡尼与胺碘酮的联合治疗可能无需早期介入治疗,或者可以推迟到儿童年龄较大时进行。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验